On Thursday morning, the full U.S. Senate Judiciary Committee will convene an executive business meeting to consider several pieces of proposed legislation aimed largely at regulating patent-related activities in the pharmaceutical sector. Although one proposed bill would call for a study into the role of intermediaries in the pharmaceutical supply chain, the remaining drafts are meant to address perceived issues related to drug patents, many of which have been made more menacing by data reports that have been refuted by U.S. government sources.

Full Article Available Here